Cannot put sound strategy together.
Even with competitors exposed, so vulnerable. Taking token initiatives described as assets to bring advanced research and discoveries, but hollow, Open book to competitors. Mismanagement of inner and outer talent and entrenchment of parochial interests.
Internal consultants at Lilly are not up to the task. They are often moved from the positions of responsibility to consultancy due to mediocre performance. Their advice is of low value. Could be interesting how this compares to similar internal consulting positions performance in other companies, like at Novo.
Having many Advisors on board but the internal strategy lacks depth and sounds sometimes amateurish and half-baked. Opposite to what Novo is trying by inviting McKinsey and other heavy weights. Strategy is still old fashioned pharma preoccupied with daily grind.
Limited career opportunities. Despite financial strength there is poor overall efficiency and performance. This is due to employment characteristics with ethnic groups following their group interests rather than company interests. Could even discriminate against Americans.
Solid pay and bonus potential+vaca time- and good meds. Way too big brother of a company though. Also pull you out of territory for trainings and town halls way too often
